489 related articles for article (PubMed ID: 20499897)
1. Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.
Lopez MF; Kuppusamy R; Sarracino DA; Prakash A; Athanas M; Krastins B; Rezai T; Sutton JN; Peterman S; Nicolaides K
J Proteome Res; 2011 Jan; 10(1):133-42. PubMed ID: 20499897
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers.
Nagalla SR; Canick JA; Jacob T; Schneider KA; Reddy AP; Thomas A; Dasari S; Lu X; Lapidus JA; Lambert-Messerlian GM; Gravett MG; Roberts CT; Luthy D; Malone FD; D'Alton ME
J Proteome Res; 2007 Apr; 6(4):1245-57. PubMed ID: 17373838
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
5. Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening.
Koster MP; Pennings JL; Imholz S; Rodenburg W; Visser GH; de Vries A; Schielen PC
Prenat Diagn; 2009 Sep; 29(9):857-62. PubMed ID: 19488973
[TBL] [Abstract][Full Text] [Related]
6. Sequential pathways of testing after first-trimester screening for trisomy 21.
Platt LD; Greene N; Johnson A; Zachary J; Thom E; Krantz D; Simpson JL; Silver RK; Snijders RJ; Goetzl L; Pergament E; Filkins K; Mahoney MJ; Hogge WA; Wilson RD; Mohide P; Hershey D; MacGregor S; Bahado-Singh R; Jackson LG; Wapner R;
Obstet Gynecol; 2004 Oct; 104(4):661-6. PubMed ID: 15458882
[TBL] [Abstract][Full Text] [Related]
7. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
Spencer K
Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
[TBL] [Abstract][Full Text] [Related]
8. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
9. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
[TBL] [Abstract][Full Text] [Related]
10. Second trimester two-step trisomy 18 screening using maternal serum markers.
Muller F; Sault C; Lemay C; Roussel-Mizon N; Forestier F; Frendo JL;
Prenat Diagn; 2002 Jul; 22(7):605-8. PubMed ID: 12124697
[TBL] [Abstract][Full Text] [Related]
11. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation.
Bahado-Singh RO; Oz AU; Gomez K; Hunter D; Copel J; Baumgarten A; Mahoney MJ
Ultrasound Obstet Gynecol; 2000 Mar; 15(3):199-204. PubMed ID: 10846774
[TBL] [Abstract][Full Text] [Related]
12. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry.
Paweletz CP; Wiener MC; Bondarenko AY; Yates NA; Song Q; Liaw A; Lee AY; Hunt BT; Henle ES; Meng F; Sleph HF; Holahan M; Sankaranarayanan S; Simon AJ; Settlage RE; Sachs JR; Shearman M; Sachs AB; Cook JJ; Hendrickson RC
J Proteome Res; 2010 Mar; 9(3):1392-401. PubMed ID: 20095649
[TBL] [Abstract][Full Text] [Related]
13. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
Benn PA; Ying J; Beazoglou T; Egan JF
Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
[TBL] [Abstract][Full Text] [Related]
14. Increased time-to-pregnancy and first trimester Down's syndrome screening.
Ranta JK; Raatikainen K; Romppanen J; Pulkki K; Heinonen S
Hum Reprod; 2010 Feb; 25(2):412-7. PubMed ID: 19945962
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
16. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
17. Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay.
Cho CK; Drabovich AP; Batruch I; Diamandis EP
J Proteomics; 2011 Sep; 74(10):2052-9. PubMed ID: 21624510
[TBL] [Abstract][Full Text] [Related]
18. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy.
Spencer K; Bindra R; Nicolaides KH
Prenat Diagn; 2003 Oct; 23(10):851-5. PubMed ID: 14558032
[TBL] [Abstract][Full Text] [Related]
19. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
20. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
